- Trial Phase
- Phase 2
- Time to Market
- At least 2-4 years away. The next catalyst is a randomized Phase 2 readout in H1 2027. If positive, a registration-enabling Phase 3 trial would then need to start, pushing potential approval to 2029 or later.
- Why 6/10
- The next hard catalyst is the randomized Phase 2 MSS CRC topline readout expected in H1 2027 (~4-9 months from now). ADG126 is Adagene's lead asset, and this readout will determine whether the 20 mg/kg dosing strategy can replicate earlier promising data in a randomized setting. While not a registrational trial, a strong result would pave the way for a Phase 3 registration trial and likely drive a significant stock move. ImpactScore 6: a dated binary within ~6-12 months on the company's major value driver, while the company has other pipeline programs and partnerships that provide diversification.
The single most important event to watch is the randomized Phase 2 MSS CRC data in H1 2027. Between now and then, look for interim data updates at medical conferences or partnership expansions. The CEO's $84K open-market purchase in August 2026 signals insider confidence. Short interest of ~3.1% of shares outstanding with ~8 days to cover provides some squeeze potential on positive news, but the 42% dilution from the April offering is a headwind for EPS and share price.
Price Chart
Executive Summary
ADG126 (muzastotug) is Adagene Inc.'s lead clinical asset and a 'masked' anti-CTLA-4 antibody using the company's proprietary SAFEbody platform. It aims to improve upon existing CTLA-4 inhibitors by activating only in the tumor microenvironment, potentially offering better safety and higher dosing. Phase 1b/2 data have shown promising response rates in MSS colorectal cancer (31-36% ORR at 20 mg/kg with Keytruda) and in first-line liver cancer (66.7% ORR triple combination). A randomized Phase 2 in MSS CRC is the key upcoming catalyst, with results expected in H1 2027. The company is well-capitalized with $127.9M cash running into late 2028 and has attracted partnerships with Sanofi and Incyte. The stock trades at ~$3.30 with strong analyst support (10 analysts: 10 Buy/Hold, 0 Sell; mean PT $10.09, implying ~205% upside). Key risks include clinical trial failure, dilution from the April 2026 $70M offering (42% share increase), and competition from other CTLA-4 agents.
How It Works
ADG126 is a 'masked' anti-CTLA-4 antibody built on Adagene's SAFEbody platform. CTLA-4 is a protein on immune T-cells that acts as a 'brake' on the immune system. Tumors exploit this brake to hide from immune attack. ADG126 is designed to be inert until it reaches the tumor microenvironment, where it gets 'unmasked' and activates the immune system to attack the cancer. This conditional activation is intended to reduce the severe side effects seen with older CTLA-4 drugs like Yervoy (ipilimumab), potentially allowing higher, more effective dosing.
Trial Status
ADG126 is being studied in multiple Phase 1b/2 trials. In microsatellite stable colorectal cancer (MSS CRC), the 20 mg/kg dose combined with Merck's Keytruda (pembrolizumab) showed a 31% confirmed overall response rate (ORR) and median progression-free survival of 15.4 months in late-line patients, compared to 13% ORR at 10 mg/kg. A randomized Phase 2 trial in MSS CRC is ongoing. In first-line hepatocellular carcinoma (HCC), a triple combination of ADG126 + atezolizumab + bevacizumab showed 66.7% ORR vs 32.5% for the control arm at AACR 2026. The drug has FDA Fast Track designation.
The Two-Sided Case
Upcoming Catalysts
- Randomized Phase 2 MSS CRC topline results expected H1 2027 (by ~June 2027)
- Potential registration trial start in 2027 once recommended dose regimen is established
- Phase 1 combination study with Incyte's TGFßR2xPD-1 bispecific (INCA33890) in MSS CRC, starting in 2026
- Phase 1/2 basket trial with Sanofi (ongoing)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Adagene Inc. PRESS-RELEASE ADAG ·Originating report